Gecaj-Gashi Agreta, Nikolova-Todorova Zorica, Ismaili-Jaha Vlora, Gashi Musli
Clinic of Anesthesiology & Intensive Care, University Clinical Centre of Kosova, 10000, Prishtina, Republic of Kosova.
Clinic of Anesthesiology & Reanimatology and Intensive Care, University Clinical Centre of Skopje, Skopje, Republic of Macedonia.
Cough. 2013 Aug 15;9:20. doi: 10.1186/1745-9974-9-20. eCollection 2013.
Fentanyl-induced cough is usually mild and transitory, but it can be undesirable in patients with increased intracranial pressure, open wounds of the eye, dissecting aortic aneurism, pneumothorax, and reactive airway disease. The aim of this study is to evaluate the efficacy of lidocaine in suppressing fentanyl-induced cough in children during induction in general anesthesia.
One hundred and eighty-six children of both sexes, aged between 4-10 years, ASA physical status I and II, and scheduled for elective surgery, were recruited for the study. Patients with a history of bronchial asthma, obstructive pulmonary disease, or infections of the respiratory tract were excluded. Patients were randomly allocated to three equal groups (n = 62) to receive 1.0 mg/kg lidocaine (Group I), 0.5 mg/kg lidocaine (Group II), or placebo (equal volume of 0.9% saline; Group III). Each was administered over 5 s one minute before intravenous (IV) administration of fentanyl 2-3 μg/kg during induction in general anesthesia. The severity of coughing was graded by counting the number of episodes of cough: mild (1-2), moderate (3-4) or severe (5 or more).
Demographic information was comparable between groups. The most frequent coughing was observed in the placebo group (Group III; 43.5%), of whom 4.8% (three patients) were graded with severe cough. In Group II, 22.6% patients had cough, of which 1.6% (one patient) was graded as severe. In Group I, 16.1% patients had cough, none of whom were graded as severe.
Our results demonstrate that IV lidocaine can markedly suppress fentanyl-induced cough in children, even in doses as low as 0.5 mg/kg.
芬太尼诱发的咳嗽通常轻微且短暂,但对于颅内压升高、眼部开放性伤口、主动脉夹层动脉瘤、气胸和反应性气道疾病患者而言可能并不适宜。本研究旨在评估利多卡因在全身麻醉诱导期抑制儿童芬太尼诱发咳嗽的效果。
招募186名年龄在4至10岁之间、美国麻醉医师协会(ASA)身体状况为I级和II级且计划进行择期手术的男女儿童参与本研究。排除有支气管哮喘、阻塞性肺疾病或呼吸道感染病史的患者。将患者随机分为三组,每组62人,分别接受1.0mg/kg利多卡因(I组)、0.5mg/kg利多卡因(II组)或安慰剂(等量0.9%生理盐水;III组)。在全身麻醉诱导期静脉注射2 - 3μg/kg芬太尼前1分钟,每组均在5秒内给药。通过计算咳嗽发作次数对咳嗽严重程度进行分级:轻度(1 - 2次)、中度(3 - 4次)或重度(5次及以上)。
各组间人口统计学信息具有可比性。安慰剂组(III组)咳嗽最为频繁(43.5%),其中4.8%(3例患者)为重度咳嗽。II组中,22.6%的患者出现咳嗽,其中1.6%(1例患者)为重度。I组中,16.1%的患者出现咳嗽,均无重度咳嗽。
我们的结果表明,静脉注射利多卡因可显著抑制儿童芬太尼诱发的咳嗽,即使剂量低至0.5mg/kg。